Rapamycin for Longevity: What the Evidence Shows About Off-Label Use and Its Risks

A Transplant Drug at the Center of Longevity Hype

Rapamycin (generic name sirolimus) was first isolated from bacteria in a soil sample from Easter Island (Rapa Nui) and developed as an immunosuppressant. In the United States it is FDA-approved to prevent kidney transplant rejection and to treat lymphangioleiomyomatosis (LAM), a rare lung disease. Using it to slow aging is off-label: no regulator has evaluated or approved it for that purpose.

The interest comes from animal research. In a landmark 2009 study from the National Institute on Aging's Interventions Testing Program, rapamycin fed to genetically diverse mice starting at 600 days of age—roughly late middle age—extended both median and maximum lifespan. Based on age at 90% mortality, lifespan increased by 14% in females and 9% in males. Few drugs have shown effects like this in mammals.

The real questions are whether any of that translates to people, and at what cost.

What Human Studies Actually Show

Human data on rapamycin for aging are limited, small and short-term.

PEARL (2025). This 48-week, double-blind, placebo-controlled, decentralized trial gave healthy adults placebo or 5 mg or 10 mg of compounded rapamycin once a week. The primary outcome—visceral fat—did not change. Adverse events were similar across groups, and blood biomarkers stayed within normal ranges. Women taking 10 mg improved in lean tissue mass and self-reported pain, and the 5 mg group reported better emotional well-being and general health; no other significant effects were found. The authors were employees of a company that provides off-label rapamycin, and the trial was not designed to measure aging or lifespan.

Immune response in older adults (2014). In elderly volunteers, the related drug everolimus improved the response to influenza vaccination by about 20% at doses that were relatively well tolerated. It is an intriguing signal, but it involved a different molecule and a short course.

A small pilot in older adults (2018). Twenty-five adults aged 70–95 took 1 mg of rapamycin or placebo daily for at least 8 weeks. There were no changes in cognitive, physical performance or self-rated health measures. Several red blood cell measures, including hemoglobin, declined slightly in the rapamycin group, though not to a clinically significant degree in that short study.

Systematic review (2024). A review of 19 human studies found that rapamycin and related drugs improved some aging-related measures in the immune, cardiovascular and skin systems, with no significant effects on endocrine, muscle or neurological measures. No serious adverse events were attributed to the drugs in healthy people, but people with age-related diseases had more infections and higher total cholesterol, LDL cholesterol and triglycerides.

The bottom line: no human study has shown that rapamycin extends lifespan or healthspan.

mTORC1, mTORC2 and Why Dosing Schedules Are Studied

Rapamycin inhibits mTOR, a nutrient-sensing pathway that regulates cell growth and autophagy (the cell's recycling system). It acutely inhibits mTOR complex 1 (mTORC1), which is thought to drive much of its lifespan effect in animals. Prolonged exposure also disrupts a second complex, mTORC2. A 2012 mouse study in Science showed that loss of mTORC2 mediates rapamycin-induced insulin resistance, and that reducing mTORC1 signaling alone could extend lifespan without impairing glucose tolerance.

That finding led researchers to test intermittent schedules in mice. A 2016 Aging Cell study identified an intermittent regimen with much smaller effects on glucose tolerance and the immune system than daily dosing.

These are mouse results. No human trial has established that any intermittent schedule makes long-term rapamycin safe or that it slows human aging. The weekly protocols that circulate in longevity clinics and online forums are extrapolations, not evidence-based dosing—and this article does not recommend any dose.

Known Risks From the FDA Label

Sirolimus prescribing information reflects decades of use in transplant patients, who usually take it daily alongside other immunosuppressants. Lower, intermittent doses may carry less risk, but these are the documented hazards:

• Boxed warning: increased susceptibility to infection and possible development of lymphoma and other malignancies, particularly skin cancer, as a result of immunosuppression.
• Blood lipids: high triglycerides and high cholesterol are among the most common adverse reactions.
• Wound healing and fluid: impaired wound healing and fluid accumulation, including swelling.
• Mouth and gut: mouth sores (stomatitis), diarrhea, nausea and abdominal pain are common.
• Lungs and kidneys: interstitial lung disease (non-infectious pneumonitis) and protein in the urine.
• Allergic reactions: hypersensitivity reactions and angioedema.
• Reproduction: it can cause fetal harm—the label recommends highly effective contraception during treatment and for 12 weeks after the last dose—and it may reduce sperm counts.
• Vaccines: live vaccines should be avoided.
• Drug interactions: sirolimus is processed by CYP3A4 and P-glycoprotein. Strong inhibitors (such as ketoconazole or clarithromycin) and strong inducers (such as rifampin) should be avoided, grapefruit juice must not be taken with it, and cannabidiol can raise its levels.

Questions Without Answers

• Long-term safety in healthy people: controlled data extend only to about one year.
• Benefit versus risk at any dose: unknown. Trials so far have measured biomarkers and body composition, not aging outcomes.
• Who, if anyone, benefits: not established.
• Product quality: compounded versions, like those used in PEARL and by some clinics, are not FDA-approved products.

If You're Considering It

This is not a decision to make based on online protocols. Talk with a physician who can review your full medical history, every medication and supplement you take (because of interactions), your infection risk and lab values such as lipids, blood counts and blood glucose—and who will monitor you over time. Rapamycin is not appropriate during pregnancy or when trying to conceive, and anyone taking it should tell every clinician who treats them, especially before surgery or vaccinations.

Keep perspective. The strongest evidence for rapamycin and longevity is still in mice. In humans, the honest answer is that we don't yet know whether the benefits outweigh the risks.